AlphAIAlphAI — Financial news for AI agents
yahoo.comSEP 192 min read$CAH

Cardinal Health Targets 13%-15% EPS Growth as Specialty Momentum Builds

Cardinal Health (CAH) targets 13%-15% EPS growth, driven by specialty platforms in oncology, urology, and autoimmune care. BioPharma Solutions grew over 30% in fiscal 2026, aiming for $1B revenue by fiscal 2028. The company expects 15%-18% adjusted operating-income growth in fiscal 2027, with contributions from recent acquisitions.

Original reporting
yahoo.com
Published Sep 19, 2026, 11:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 20, 2026, 12:20 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Cardinal Health Targets 13%-15% EPS Growth as Specialty Momentum Builds — source image
Source · yahoo.com
Decision brief

The 30-second read

$CAHBullishMed
01

Why it matters

Guidance signals stronger earnings trajectory, but execution risk remains.

02

Market read

New EPS guidance could move CAH stock and influence sector sentiment.

03

What to watch

Potential tariff impacts and policy changes could offset projected growth.

Relevance 7/10Novelty 7/10Timing: guidance release

Background

Cardinal Health provides distribution and specialty services to pharmacies and health systems.

Company-level read

Ticker impact

$CAHBullishMedium confidence
Context

Cardinal Health announced EPS growth target of 13%-15% and reported >30% growth in its BioPharma Solutions business.

Expected impact

Potential upside for CAH as investors price in higher EPS growth.

Evidence & confidence

Guidance is new and material, but scale is moderate; market may react positively.

Market effects

Sector

Positive outlook for healthcare distribution and specialty pharma sector.

Regional

U.S. healthcare services segment may see modest uplift.

Global

Limited to U.S. market; no direct global ripple.

Counterpoint

What could challenge this read

Growth targets may be optimistic given pricing pressures and policy risks.

Key entities

  • company
    Cardinal Health

    Healthcare services and products distributor.

Read at source← All news

Related articles

OCT 3
$CAHMed

How CVS Deal Extension At Cardinal Health (CAH) Has Changed Its Investment Story

Cardinal Health (CAH) extended its pharmaceutical distribution agreement with CVS Health until 2032, reaffirming its fiscal 2027 non-GAAP EPS growth guidance of 13% to 15%. The extension secures a key partner, supporting Cardinal's strategy to shift toward higher-margin services. Analysts expect revenue of $297.6 billion and earnings of $3.0 billion by 2029. The company's upcoming Q1 results on November 5 will provide further insights.

simplywall.st2 min
OCT 1
$CAHHigh

Why is Cardinal Health stock rallying today?

Cardinal Health (CAH) stock rose 3.8% after extending its pharmaceutical distribution agreement with CVS Health (CVS) until 2032, removing investor uncertainty. The company reaffirmed its FY2027 EPS guidance of $12.40-$12.60. Today is the ex-dividend date for its quarterly dividend of $0.516 per share. The stock reached $235.95 intraday, with broader market gains providing a supportive backdrop.

investing.com2 min
OCT 1
$MCKMed

McKesson (MCK) and Cardinal Health Extend CVS Health Distributio

McKesson (MCK) and Cardinal Health renewed their pharmaceutical distribution agreements with CVS Health, extending contracts through June 2032. Both companies reaffirmed their fiscal 2027 earnings guidance. McKesson's stock is trading at $890.28, 6.8% above its GF Value of $833.49, with a GF Score of 86/100. Insider sales totaled $28.3 million over the past year, while 15 premium gurus hold MCK with a net positive addition.

gurufocus.com2 min
OCT 1
$CAHMed

Why Is Cardinal Health and McKesson Stock Trading Higher Today - CVS Health (NYSE:CVS), McKesson (NYSE:MC

Cardinal Health (CAH) and McKesson (MCK) extended their distribution agreements with CVS Health (CVS) until 2032. Cardinal Health reaffirmed its 2027 adjusted earnings guidance of $12.40-$12.60 per share, while McKesson reiterated its 2027 outlook of $44.20-$45 per share. Both companies' stocks rose on the news, with McKesson up 4.28% and Cardinal Health up 2.94%.

benzinga.com2 min